Dusa not one trick pony, $230M is fair offer, says Sun
This article was originally published in Scrip
Sun Pharmaceutical Industries $230 million acquisition of the dermatology firm, Dusa Pharmaceutical, brings with it significant limited competition potential in the US and other markets, though the Indian firm appears keen to buy more and buy bigger. Dusa is focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.